Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2025
Date Filed: April 22, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves as a notification of corporate actions rather than a financial results report.
Material Changes
The primary material change disclosed in this filing is the submission of Exhibit 99.1, titled "New Options - Top 20 Holders and Range of Units." This indicates the grant or issuance of new equity options to specific holders.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a procedural filing incorporating exhibits by reference into existing Registration Statements (Forms S-8 and F-3).
Investor Verification Checklist
- Review the attached Exhibit 99.1 to determine the specific number of new options granted and the identity of the Top 20 holders.
- Verify the impact of these new options on the company's total outstanding share count and potential dilution.
- Confirm the terms of the new options (e.g., exercise price, vesting schedule) which are likely detailed in the exhibit rather than the cover letter.
- Check the referenced Registration Statements (S-8 and F-3) for the context of these option grants within the company's broader capital structure.